GlycoEra AG’s Post

We are delighted to announce further success in our collaboration with AstraZeneca. Using BenevolentAI’s AI-drug discovery platform, a novel target for systemic lupus erythematosus (SLE) has been identified. 🎯 The target has been experimentally validated by AstraZeneca and added to its discovery portfolio. Following the heart failure milestone, it’s the second target to be selected this year from our extended collaboration. 📣 Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca said: “By combining our immunology disease area expertise and BenevolentAI’s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.” SLE, or lupus, can cause inflammation, pain and damage – often affecting the organs and joints in severe cases. Extreme fatigue and cognitive issues are also common, along with comorbidities including cardiovascular disease. Read more here: https://lnkd.in/e2mq8haw

Looking forward meeting you in the poster session A71 at ATS San Diego today. ‼️CUTTING EDGE TECHNOLOGIES FOR LUNG DISCOVERY 🫁 Poster: 📌„Effective Pharmacological Modulation of Biomarkers in Lung Tissue of Pulmonary Fibrosis Patients Ex Vivo“ Don’t miss the other poster contributions of my colleagues: 📅 On Sunday, May 19: ▶ Chip cytometry for simultaneous measurement of protein and mRNA markers on single cell level ▶ Ex Vivo Testing of Antifibrotic Drugs in a Long-term Culture of Precision-cut Lung Slices (PCLS) ▶ Ex-vivo Evaluation of the Potential for Narrow Spectrum Kinase Inhibitors as a Treatment for Idiopathic Pulmonary Fibrosis ▶ CXCL10+ Monocyte-derived Macrophages Are Potential Drivers of TH17.1 Inflammation in Pulmonary Sarcoidosis 📅 On Monday, May 20: ▶ Comprehensive analysis of bronchoalveolar lavage fluid by validating ELISA and MSD systems for 23 biomarkers ▶ Integrated In Vitro/Ex Vivo Assessment of Efficacy and Respiratory Toxicity for Accelerated Respiratory Drug Development ▶ Combined Rhinovirus Infection and Cigarette Smoke Exposure of Normal Human Epithelial Cells and Distal Lung Tissue Ex Vivo Induces Dysregulation of Human Airway Basal Cells 📅 On Tuesday, May 21: ▶ Transcriptomic characterization of type 2 innate lymphoid cells from asthma patients in response to prostaglandin D2 metabolites ▶ Inhaled LNP-formulated siRNA Inhibits Human Parainfluenza Virus Type 3 Infection: From Bench to Bedside ▶ Role of Tumor Necrosis Factor Superfamily Member 10 (TNFSF10) in SARS-CoV2-infection-associated Lung Damage

Exciting news from Mestag!

Our inaugural issue of The Quill Quartet is here! Four things you might have missed in immunology/rheumatology from the past couple of months. Read more: ▪️Circulating regulatory T cells: https://buff.ly/4f9Qc1i ▪️Digital health in rheumatoid arthritis (RA): https://buff.ly/3W8tgXq ▪️Tyenne approved by the FDA: https://buff.ly/3Wr3Kht ▪️ Long-term safety and efficacy of CAR-T cell treatment in severe and treatment refractory autoimmune disease: https://buff.ly/4fb2LZY More about the CAR-T study: In data presented at EULAR 2024, patients with refractory lupus (SLE n=8), systemic sclerosis (SSc, n=4), and idiopathic inflammatory myositis (IIM=3) were treated with experimental CD19-targeting CAR T cell therapy. At ≥1 year after treatment (median follow-up of 18 months), all 15 patients had stopped immunosuppressive therapy. All patients achieved remission as defined by DORIS remission (SLE), all IIM patients reached ACR/EULAR major response (IIM) and improvement in the EUSTAR activity index (SSc).

We are excited to share new pharmacological characterization data on our mas-related G-protein coupled receptor X2 (MRGPRX2) program at IMMUNOLOGY 2024, the Annual Meeting of the American Association of Immunologists in Chicago. As leaders in the development of MRGPRX2, we believe this new therapeutic class could play an important role in debilitating inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis and asthma. We will also present new important invitro and in-vivo pharmacology data on our Protein Kinase C Theta (PKCϴ) program. Please join us at the conference May 3-7 when we present our posters. https://lnkd.in/e7KwtVNk #AAI2024 #immunology #inflammation

Celebrating Rare Disease Research on the Rarest Day of the Year - Moderna's Rare Disease portfolio includes therapies targeting methylmalonic acidemia (MMA), propionic acidemia (PA), glycogen storage disease (GSD1A) and Phenylketonuria (PKU). We're targeting up to 4 product launches in the next 5 years!!! Check out the article below and if you are a Pediatrics MD or an experienced Clinical Scientist in the industry, let's connect to discuss the possibilities of Moderna! #nowhiring #rarediseaseday #clinicaldevelopment

Chronic Rhinosinusitis with Primary Antibody Deficiency: An Underrecognized Condition Primary antibody deficiency (PAD) can occur in up to 50% of patients with recalcitrant chronic rhinosinusitis (CRS), making a multidisciplinary collaboration with clinical immunology crucial to optimal management of the condition. https://ow.ly/C7zM50RyAiQ

I invite you to read the following Editorial, which resumes a group of exciting papers related to ocular immunology #womeninscience #womeninophthalmology #womeninimmunology https://lnkd.in/g9WkV3be

🎉 Thank you to everyone who joined our LIVE virtual discussion on Systems Immunology! In case you missed it, or want to watch it again, here's the link to the recording: https://lnkd.in/gw-dWv3n Don't forget, you can also review our April webinar! Stay tuned for more upcoming events from PLMI! #PLMI #predictivemedicine #systemsimmunology #freeevent #integrativemedicine #integrativehealth #functionalmedicine

In a new study, researchers at Weill Cornell Medicine, including CRI Lloyd J. Old STAR Dr. Gregory Sonnenberg, identified a previously unknown link between two key pathways that regulate the immune system in mammals. "Until now, most research on CTLA-4 focused on T cells, another type of immune cell. By uncovering that it is selectively upregulated on ILC3s by IL-23, this demonstrates that we should be thinking about these pathways more broadly to develop more selective therapeutics," describes Dr. Sonnenberg. Discover: https://bit.ly/4b7Msdp #Immunotherapy #CancerResearch #IBD #TCells